When a company called Kardigan drops a $254M Series B less than a year after launch, you know this isn’t just another biotech headline, it’s a statement. And not the kind your PR team drafts at 2 a.m. after a crisis. This is a power move from a crew that already changed how the world looks at heart disease once and decided they weren’t done.
Kardigan was born from the minds behind MyoKardia, the same squad that took mavacamten from whiteboard to Bristol Myers Squibb’s $13.1B buyout. Now, co-founders Tassos Gianakakos (CEO & Chair), Jay Edelberg, M.D., Ph.D. (CMO), Bob McDowell, Ph.D. (CSO), Leslie Leinwand, Ph.D., and Elizabeth McNally, M.D., Ph.D. have rebooted the blueprint for cardiovascular medicine. They’re not chasing symptoms, they’re chasing cures.
ARCH Venture Partners and Sequoia Heritage led this $254M B-round, with Fidelity and T. Rowe Price Investment Management joining the table. Stack that on the $300M Series A from January, and Kardigan’s raised a cool $554M in less than 12 months. Yeah, that’s not momentum, that’s velocity.
From its South San Francisco HQ, Kardigan’s moving at a clip most pharma veterans would call impossible. The team’s advancing 3 late-stage programs simultaneously: danicamtiv for genetic dilated cardiomyopathy, tonlamarsen for acute severe hypertension, and ataciguat for calcificaorticvalve stenosis. The kicker? All 3 tackle diseases that medicine’s been politely ignoring for decades.
When they acquired Prolaio in March, it wasn’t just a data play, it was a declaration. Their cardiac intelligence engine now pulls real-world patient data, AI insights, and molecular science into a single rhythm. Picture it like a DJ mixing beats in real time, except the crowd is global heart patients, and the drop might just save lives.
The numbers don’t lie. Positive Phase 2a data for danicamtiv already landed at HFSA 2025. The KINSHIP-DCM Phase 3 is set for late 2025. Multiple readouts are queued for 2026. This isn’t biotech’s usual slow dance; it’s a sprint toward functional cures.
So yeah, the market’s watching. The VC world’s listening. And every cardiologist on the planet just felt their pulse quicken. Kardigan’s not patching hearts, it’s reprogramming how we treat them. And that $254M? Consider it fuel for the comeback tour of a lifetime.
